Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
(2015) In Lancet Neurology 14(11). p.1091-1100- Abstract
- Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8159005
- author
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Lancet Neurology
- volume
- 14
- issue
- 11
- pages
- 1091 - 1100
- publisher
- Lancet Publishing Group
- external identifiers
-
- pmid:26432181
- wos:000362975200013
- scopus:84944039741
- ISSN
- 1474-4465
- DOI
- 10.1016/S1474-4422(15)00245-8
- language
- English
- LU publication?
- yes
- id
- 977e84f2-dd6a-4d84-9469-097a0e561521 (old id 8159005)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26432181?dopt=Abstract
- date added to LUP
- 2016-04-01 10:26:24
- date last changed
- 2024-02-21 16:25:28
@article{977e84f2-dd6a-4d84-9469-097a0e561521, abstract = {{Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.}}, author = {{Bigal, Marcelo E and Edvinsson, Lars and Rapoport, Alan M and Lipton, Richard B and Spierings, Egilius L H and Diener, Hans-Christoph and Burstein, Rami and Loupe, Pippa S and Ma, Yuju and Yang, Ronghua and Silberstein, Stephen D}}, issn = {{1474-4465}}, language = {{eng}}, number = {{11}}, pages = {{1091--1100}}, publisher = {{Lancet Publishing Group}}, series = {{Lancet Neurology}}, title = {{Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.}}, url = {{http://dx.doi.org/10.1016/S1474-4422(15)00245-8}}, doi = {{10.1016/S1474-4422(15)00245-8}}, volume = {{14}}, year = {{2015}}, }